A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage
ABSTRACT Ceftaroline (CPT) is a broad-spectrum agent with potent activity against methicillin-resistant Staphylococcus aureus (MRSA). The sequence type 5 (ST5) Chilean-Cordobés clone, associated with CPT nonsusceptibility, is dominant in Chile, a region with high rates of MRSA infections. Here, we a...
- Autores:
-
Khan, Ayesha
Rivas, Lina M.
Spencer, Maria
Martinez, Rodrigo
Lam, Marusella
Rojas, Pamela
Porte, Lorena
Silva, Francisco
Braun, Stephanie
Valdivieso, Francisca
Mvlhauser, Margareta
Lafourcade, Mónica
Miller, William
García, Patricia
Arias, Cesar
Munita, José M.
- Tipo de recurso:
- Fecha de publicación:
- 2019
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/2020
- Palabra clave:
- Staphylococcus aureus resistente a meticilina
Bacilos grampositivos formadores de endosporas
Pruebas Antimicrobianas de difusión por disco
Ceftaroline
Disk diffusion
Etest
Breakpoints
- Rights
- License
- Attribution 4.0 International
id |
UNBOSQUE2_175c3c6eaace542a569964a4f7bd3399 |
---|---|
oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/2020 |
network_acronym_str |
UNBOSQUE2 |
network_name_str |
Repositorio U. El Bosque |
repository_id_str |
|
dc.title.spa.fl_str_mv |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
dc.title.translated.none.fl_str_mv |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
title |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
spellingShingle |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage Staphylococcus aureus resistente a meticilina Bacilos grampositivos formadores de endosporas Pruebas Antimicrobianas de difusión por disco Ceftaroline Disk diffusion Etest Breakpoints |
title_short |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
title_full |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
title_fullStr |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
title_full_unstemmed |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
title_sort |
A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineage |
dc.creator.fl_str_mv |
Khan, Ayesha Rivas, Lina M. Spencer, Maria Martinez, Rodrigo Lam, Marusella Rojas, Pamela Porte, Lorena Silva, Francisco Braun, Stephanie Valdivieso, Francisca Mvlhauser, Margareta Lafourcade, Mónica Miller, William García, Patricia Arias, Cesar Munita, José M. |
dc.contributor.author.none.fl_str_mv |
Khan, Ayesha Rivas, Lina M. Spencer, Maria Martinez, Rodrigo Lam, Marusella Rojas, Pamela Porte, Lorena Silva, Francisco Braun, Stephanie Valdivieso, Francisca Mvlhauser, Margareta Lafourcade, Mónica Miller, William García, Patricia Arias, Cesar Munita, José M. |
dc.subject.decs.spa.fl_str_mv |
Staphylococcus aureus resistente a meticilina Bacilos grampositivos formadores de endosporas Pruebas Antimicrobianas de difusión por disco |
topic |
Staphylococcus aureus resistente a meticilina Bacilos grampositivos formadores de endosporas Pruebas Antimicrobianas de difusión por disco Ceftaroline Disk diffusion Etest Breakpoints |
dc.subject.keywords.spa.fl_str_mv |
Ceftaroline Disk diffusion Etest Breakpoints |
description |
ABSTRACT Ceftaroline (CPT) is a broad-spectrum agent with potent activity against methicillin-resistant Staphylococcus aureus (MRSA). The sequence type 5 (ST5) Chilean-Cordobés clone, associated with CPT nonsusceptibility, is dominant in Chile, a region with high rates of MRSA infections. Here, we assessed the in vitro activity of CPT against a collection of MRSA isolates collected between 1999 and 2018 from nine hospitals (n 320) and community settings (n 41) in Santiago, Chile, and evaluated performance across testing methodologies. We found that our hospitalassociated isolates exhibited higher CPT MIC distributions (MIC50 and MIC90 of 2 mg/liter) than the community isolates (MIC50 and MIC90 of 0.5 mg/liter), a finding that was consistent across time and independent of the culture source. High proportions (64%) of isolates were CPT nonsusceptible despite the absence of CPT use in Chile. Across methodologies, the Etest underestimated the MIC relative to the gold standard broth microdilution (BMD) test (MIC50 and MIC90 of 1 and 1.5 mg/liter, respectively). There was low (51%) categorical agreement (CA) between Etest and BMD results across CLSI and EUCAST breakpoints. The recent revision of CLSI guidelines abolished “very major error” (VME) from the previous guidelines (81%), which perform similarly to the EUCAST guidelines. The level of concordance between CLSI and EUCAST for BMD testing and Etest was 95%. Disk diffusion performed poorly relative to BMD under CLSI (CA, 55%) and EUCAST (CA, 36%) guidelines. Comparison of EUCAST to CLSI for disk diffusion (with EUCAST used as the reference) showed low agreement (CA, 25%; VME, 70%). In summary, CPT-nonsusceptible MRSA are dominant in clinical settings in Chile. Our results provide data to support the reevaluation of CPT breakpoints and to improve agreement across methodologies and agencies. |
publishDate |
2019 |
dc.date.issued.none.fl_str_mv |
2019 |
dc.date.accessioned.none.fl_str_mv |
2020-03-09T14:24:49Z |
dc.date.available.none.fl_str_mv |
2020-03-09T14:24:49Z |
dc.type.spa.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.local.spa.fl_str_mv |
artículo |
dc.identifier.issn.none.fl_str_mv |
0095-1137 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/2020 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1128/JCM.00798-19 |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
dc.identifier.repourl.none.fl_str_mv |
repourl:https://repositorio.unbosque.edu.co |
identifier_str_mv |
0095-1137 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co |
url |
http://hdl.handle.net/20.500.12495/2020 https://doi.org/10.1128/JCM.00798-19 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofseries.spa.fl_str_mv |
Journa of Clinical Microbiology, 0095-1137, Vol. 57, Nro. 9, 2019, p.1-11 |
dc.relation.uri.none.fl_str_mv |
https://jcm.asm.org/content/57/9/e00798-19 |
dc.rights.*.fl_str_mv |
Attribution 4.0 International |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
dc.rights.local.spa.fl_str_mv |
Acceso abierto |
dc.rights.accessrights.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf183 |
dc.rights.creativecommons.none.fl_str_mv |
2019 |
rights_invalid_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Acceso abierto http://purl.org/coar/access_right/c_abf183 2019 http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
American Society for Microbiology |
dc.publisher.journal.spa.fl_str_mv |
Journa of Clinical Microbiology |
institution |
Universidad El Bosque |
bitstream.url.fl_str_mv |
https://repositorio.unbosque.edu.co/bitstreams/675292a6-a264-4e8c-b70a-59be7d72a0d8/download https://repositorio.unbosque.edu.co/bitstreams/42f171a4-63e5-4b02-8f58-a781ba32ce5a/download https://repositorio.unbosque.edu.co/bitstreams/3ad987d0-09a2-46d9-ba1e-75da48e803b7/download https://repositorio.unbosque.edu.co/bitstreams/c040f657-b6bd-4e24-adc9-d0481de6525c/download https://repositorio.unbosque.edu.co/bitstreams/1366a3a0-ec44-4375-9dc9-096de3fd1e36/download |
bitstream.checksum.fl_str_mv |
0175ea4a2d4caec4bbcc37e300941108 8a4605be74aa9ea9d79846c1fba20a33 7c50a9a2622c7f76e8e74eb7b6c0bc03 123a42d4cec5d4998da9f4fd6cec0de9 bdd02f267bfd0aa27274109907daeb31 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad El Bosque |
repository.mail.fl_str_mv |
bibliotecas@biteca.com |
_version_ |
1814100745851502592 |
spelling |
Khan, AyeshaRivas, Lina M.Spencer, MariaMartinez, RodrigoLam, MarusellaRojas, PamelaPorte, LorenaSilva, FranciscoBraun, StephanieValdivieso, FranciscaMvlhauser, MargaretaLafourcade, MónicaMiller, WilliamGarcía, PatriciaArias, CesarMunita, José M.2020-03-09T14:24:49Z2020-03-09T14:24:49Z20190095-1137http://hdl.handle.net/20.500.12495/2020https://doi.org/10.1128/JCM.00798-19instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengAmerican Society for MicrobiologyJourna of Clinical MicrobiologyJourna of Clinical Microbiology, 0095-1137, Vol. 57, Nro. 9, 2019, p.1-11https://jcm.asm.org/content/57/9/e00798-19Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf1832019http://purl.org/coar/access_right/c_abf2A multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineageA multicenter study to evaluate ceftaroline breakpoints: Performance in an area with high prevalence of methicillin- resistant Staphylococcus aureus sequence type 5 lineagearticleartículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Staphylococcus aureus resistente a meticilinaBacilos grampositivos formadores de endosporasPruebas Antimicrobianas de difusión por discoCeftarolineDisk diffusionEtestBreakpointsABSTRACT Ceftaroline (CPT) is a broad-spectrum agent with potent activity against methicillin-resistant Staphylococcus aureus (MRSA). The sequence type 5 (ST5) Chilean-Cordobés clone, associated with CPT nonsusceptibility, is dominant in Chile, a region with high rates of MRSA infections. Here, we assessed the in vitro activity of CPT against a collection of MRSA isolates collected between 1999 and 2018 from nine hospitals (n 320) and community settings (n 41) in Santiago, Chile, and evaluated performance across testing methodologies. We found that our hospitalassociated isolates exhibited higher CPT MIC distributions (MIC50 and MIC90 of 2 mg/liter) than the community isolates (MIC50 and MIC90 of 0.5 mg/liter), a finding that was consistent across time and independent of the culture source. High proportions (64%) of isolates were CPT nonsusceptible despite the absence of CPT use in Chile. Across methodologies, the Etest underestimated the MIC relative to the gold standard broth microdilution (BMD) test (MIC50 and MIC90 of 1 and 1.5 mg/liter, respectively). There was low (51%) categorical agreement (CA) between Etest and BMD results across CLSI and EUCAST breakpoints. The recent revision of CLSI guidelines abolished “very major error” (VME) from the previous guidelines (81%), which perform similarly to the EUCAST guidelines. The level of concordance between CLSI and EUCAST for BMD testing and Etest was 95%. Disk diffusion performed poorly relative to BMD under CLSI (CA, 55%) and EUCAST (CA, 36%) guidelines. Comparison of EUCAST to CLSI for disk diffusion (with EUCAST used as the reference) showed low agreement (CA, 25%; VME, 70%). In summary, CPT-nonsusceptible MRSA are dominant in clinical settings in Chile. Our results provide data to support the reevaluation of CPT breakpoints and to improve agreement across methodologies and agencies.CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908https://repositorio.unbosque.edu.co/bitstreams/675292a6-a264-4e8c-b70a-59be7d72a0d8/download0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.unbosque.edu.co/bitstreams/42f171a4-63e5-4b02-8f58-a781ba32ce5a/download8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALKhan, Ayesha.pdfKhan, Ayesha.pdfapplication/pdf527817https://repositorio.unbosque.edu.co/bitstreams/3ad987d0-09a2-46d9-ba1e-75da48e803b7/download7c50a9a2622c7f76e8e74eb7b6c0bc03MD51THUMBNAILKhan, Ayesha.pdf.jpgKhan, Ayesha.pdf.jpgIM Thumbnailimage/jpeg12733https://repositorio.unbosque.edu.co/bitstreams/c040f657-b6bd-4e24-adc9-d0481de6525c/download123a42d4cec5d4998da9f4fd6cec0de9MD54TEXTKhan, Ayesha.pdf.txtKhan, Ayesha.pdf.txtExtracted texttext/plain52569https://repositorio.unbosque.edu.co/bitstreams/1366a3a0-ec44-4375-9dc9-096de3fd1e36/downloadbdd02f267bfd0aa27274109907daeb31MD5520.500.12495/2020oai:repositorio.unbosque.edu.co:20.500.12495/20202024-02-07 02:42:06.822http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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 |